Beagle狗肾细胞及用于制备乙脑活疫苗的研究

Ｂｅａｇｌｅ乳狗（５－１０日龄）肾块用热消化法制成细胞批放液氮保存,检定合格后做下列试验：（１）复苏培养长满单层后更换维持液,其细胞能维持４天以上,克服了常规消化培养细胞维持时间短（３６小时）的缺陷。（２）传代１４－２株病毒时,１代病毒的滴度即达６．０４－６．２４ＬｏｇＰＦＵ／ｍｌ,１代后的各代（至１１代）病毒滴度无明显提高。（３）该细胞接种１４－２株病毒时不产生明显的破坏性病变（ＣＰＥ）,在收毒前采取冻溶１次比冻溶前的病毒滴度提高０．２７－０．５ＬｏｇＰＦＵ／ｍｌ。以ＢＤＫ细胞传１代的１４－２株病毒作生产毒种,收毒前冻溶１次等工艺法制备五批疫苗,全面检定结果均符合《乙脑活疫苗规程》的质量标准。其中病毒滴度为６．０９－６．２４ＬｏｇＰＦＵ／ｍｌ;免疫效价（ＩＤ５０＝ｍｌ）为１．９－４．０×１０－５,与相同滴度的原毒株１４－２ＰＨＫ苗对照无明显差异（ｔ＝０．９６８Ｐ＞０．０５）,表明其免疫原性与原毒株相似。     

狂犬病毒在Vero细胞上的适应传代研究

我国目前用于预防狂犬病的疫苗主要是地鼠肾细胞狂犬病疫苗,由于其所用毒种是脑毒种,不仅容易导致外源因子污染,还会将脑组织成分带入疫苗。为了排除鼠脑毒种带来的外源因子污染,应用Vero细胞做基质生产液体毒种,可以得到理想的病毒滴度,而且免疫原性也较好。1材料与方法1．1材料1．1．1病毒株CTN－1V5由中国药品生物制品检定所提供。1．1．2细胞及其培养Vero细胞来源于ATCC,用常规方法培养。1．2方法1．2．1毒种的传代方法取CTN－1V5干燥毒种稀释后与Vero细胞混种于培养液中,用199培养液,33℃培养168h收获病毒液,如此连续…     

狂犬病毒CTN—1株在Vero细胞上的适应传代研究

本文报导了用我国狂犬病毒固定毒人二倍体细胞适应株（ＣＴＮ－１）进行Ｖｅｒｏ细胞适应传代研究。通过连续传代培养,滴度可达８．０１ｏｇＬＤ５０／ｍｌ,达到了ＷＨＯ规定的不需浓缩的标准。病毒用０．０１ＭＯＩ感染细胞其产量与１Ｍｏｌ感染量相仿。病毒增殖高峰在４－５天,维持达１５天无明显下降,且可连续收获４－５次。因此,该毒种符合ＷＨＯ提出的疫苗生产毒种要求,可用于狂犬病疫苗生产。     

体外培养大鼠星形细胞的缺糖缺氧性损伤及药物的保护

本实验用大鼠星形细胞体外培养模型,观察了细胞在不同条件下乳酸脱氨酶（ＬＤＨ）的漏出。发现当去掉葡萄糖后,细胞缺氧５和７ｈ后ＬＤＨ漏出明显增加,５ｂ为５９．７±２５．３Ｕ／ｍｇ蛋白（对照组２４．７±１６．３,Ｐ＜０．０５）,７ｈ为６８．３±８９Ｕ／ｍｇ蛋白（对照组３９．９±２１２,Ｐ＜０．０１）。用３－氧－甲基－［１－￣３Ｈ］－Ｄ－葡萄糖摄取法测量细胞体积,结果显示缺糖缺氧５ｈ后细胞明显肿胀,从对照组的４．１±１．２增加到８．１±３．２μｌ／ｍｇ蛋白（Ｐ＜０．０１）。丹参有效成分７６４－３在０．５至５０μｍｏｌ／Ｌ时能减少缺糖缺氧细胞ＬＤＨ漏出;在５０μｍｏｌ／Ｌ时能减小缺糖缺氧细胞的体积。谷氨酸受体拮抗剂ＤＮＱＸ（６,７－ｄｉｎｉｔｒｏｑｕｉｎｏｘａｌｉｎｅ－２,３ｄｉｏｎｅ）５０μｍｏｌ／Ｌ能减轻星形细胞肿胀和ＬＤＨ漏出。     

转基因小鼠用作脊髓灰质炎活疫苗神经毒力实验动物模型的研究

选用Ⅲ型脊髓灰质炎病毒,３批活疫苗样吕（ＷＨＯ／Ⅲ参考制品,９３／３６３和３Ｊ两批猴体神经毒力实验不合格的疫苗）和１株标准强毒株（Ｌｅｏｎ）,脊髓内注入携带有人细胞脊髓灰质炎病毒受体基因的转基因小鼠（ＰＶＲＴｇ２１）。临床和组织病理学检查表明,Ｌｅｏｎ病毒的毒力极强,２．０ｌｏｇ１０ＴＣＩＤ５０可使１００％小鼠麻痹和死亡,ＷＨＯ／Ⅲ疫苗参考制品毒力最弱,５．５ｌｏｇ１０ＣＩＤ５０才能使８１．７％小     

地鼠肾细胞培养的CTN株狂犬病新疫苗研究

应用细胞毒种代替豚鼠脑毒种制备狂犬病地鼠肾细胞纯化疫苗。将狂犬病毒CTN株在原代地鼠肾细胞（PHKC）传代适应,用病毒培养液上清作为生产用毒种,结果通过在PHKC传10多代,适应后病毒滴度达到了7.0LogLD50/ml,并应用适应株（CTN－LS－HK）细胞毒种制备三批疫苗,其效力在6.11-6.55IU/ml,高于用aG株豚鼠脑毒种制备的三批疫苗效力（3.77-5.85IU/ml)。     

大规模区带离心纯化Vero细胞乙脑疫苗

本文报道一种适合疫苗生产的大规模纯化Ｖｅｒｏ细胞乙脑疫苗的方法。原疫苗经适当浓缩和去除ＤＮＡ处理后,用不连续蔗糖梯度（３６％和６０％）。３２６００ｇ,速率区带离心４ｈ。纯化后疫苗的效力比中国参考疫苗高出６倍以上,补体结合抗原比中国参考疫苗高４～８倍。总蛋白含量低于３０μｇ／ｍＬ,牛血清含量降至０．５μｇ／ｍＬ以下,细胞残余ＤＮＡ低于１００ｐｇ／０．５ｍＬ。用此法连续制备三批纯化疫苗,其纯度和效力均高于日本鼠脑纯化疫苗。此法对于制备其它纯化Ｖｅｒｏ细胞疫苗也具有一定的参考意义。     

不同代次毒种乙脑减毒活疫苗的滴度和安全性实验结果比较

为比较不同代次的乙脑毒种在疫苗制备过程中对疫苗质量的影响,特制备不同代次的工作种子SA14 14 2PHK7、PHK8、PHK9,检定合格后,分别用这几批毒种制备乙脑减毒活疫苗,检定和比较疫苗的滴度和各项安全性指标。实验表明SA14 -14 -2PHK7、PHK8和PHK9三个代次的乙脑毒种制备的乙脑疫苗平均滴度为 6. 43lgPFU/ml;乳鼠传代返祖试验均值为 1. 1lgLD50 /0. 03ml;致病力均为阴性。证实乙脑毒种SA14 -14 -2 10代以内的生物学特性是稳定的,对疫苗的影响无显著差异。10代以内的乙脑毒种可安全的用于疫苗生产。     

血小板生长因子(PDGF-BB)刺激体外培养兔肺动脉平滑肌细胞DNA和蛋白质合成

应用细胞培养、３Ｈ－ＴｄＲ和３Ｈ－Ｌｅｕｃｉｎｅ掺入方法,观察血小板生长因子ＢＢ（Ｐｌａｔｅｌｅｔ－ｄｅｒｉｖｅｄＧｒｏｗｔｈＦａｃｔｏｒＢＢ）对体外培养兔肺动脉平滑肌细胞ＤＮＡ和蛋白质合成的影响。结果表明：（１）当ＰＤＧＦ－ＢＢ浓度为１０ｎｇ／ｍｌ时,３Ｈ－ＴｄＲ掺入值已较对照组显著增高（６２６２．５±４１２．９ｖｓ８３３．５±１２４．０,Ｐ＜０．０５）;当ＰＤＧＦ－ＢＢ浓度为２０ｎｇ／ｍｌ时,３Ｈ－Ｌｅｕｃｉｎｅ掺入值亦较对照线显著增高（１０２１２．８±６３８．３ｖｓ７３４０．３±１１９７．９,Ｐ＜０．０５）。（２）ＰＤＧＦ－ＢＢ浓度在５－２５ｎｇ／ｍｌ范围内,３Ｈ－ＴｄＲ,３Ｈ－Ｌｅｕｃｉｎｅ掺入值与剂量直线相关（ｒＤＮＡ＝０．９７,ｒｐｒｏｔ＝０．９０Ｐ＜０．０５）。说明ＰＤＧＦ－ＢＢ刺激体外培养兔肺动脉平滑肌细胞ＤＮＡ和蛋白质合成。     

兴奋性氨基酸介导的膜电流可被吗啡阻断

在Ｓｐｒａｙｕｅ－Ｄａｗｉｅｙ大鼠的含有孤束核中央亚核及疑核神经元密集区的脑薄片上,吗啡（３—５ｐｍｏｌ）对疑核细胞内记录到的自发兴奋性突触后电位有抑制作用;向灌流液内注入吗啡可使电刺激孤束核在疑核记录到的兴奋性突触后电位的幅度降低７１．１±６．２％（Ｐ＜Ｏ．００１）,纳洛酮（５０ｎｍｏｌ／Ｌ）可翻转这种抑制效应;含有１０μｍｏｌ／Ｌ吗啡的灌流液对ＮＭＤＡ（０．５—１ｐｍｏｌ）、乙酰胆碱（３ｐｍｏｌ）及ＱＵｉｓｑｕａｌａｔｅ（０．１—０．５ｐｍｏｌ）引起的细胞膜去极化有不同程度的抑制作用,分别为３８．１±５．７％（Ｐ＜０．００１）,３２．８±５．５％（Ｐ＜０．０１）和２９．６±７．１％（Ｐ＜０．０５）。这些结果可能是由于吗啡兴奋μ和δ受体后,增加了Ｋ＋电流而降低Ｎａ＋,Ｃａ２＋离子通透性的缘故。     

Preparation of a purified, inactivated Japanese encephalitis (JE) virus vaccine in Vero cells

An attenuated Japanese encephalitis (JE) virus SA14-14-2 (PDK) was adapted to Vero cells, a continuous cell line that has been licensed for human vaccine production, by serial passages. The resulting virus was purified by tangential flow ultrafiltration followed by sucrose density gradient ultracentrifugation, giving 2.3 mg purified virus per liter of culture supernatant. Treatment with 0.05% formalin for 4 days at 22 °C completely inactivated viral infectivity while preserving its antigenicity. The purified, inactivated JE virus was formulated with alum hydroxide and administered to mice by intraperitoneal route. In terms of its ability to induce anti-JE neutralizing antibody and to protect the immunized animal against neurovirulent virus challenge, the purified, inactivated JE virus formulated with alum was equivalent to the exiting commercial mouse brain-derived vaccine (JE-VAX, Aventis Pasteur Inc.).     

狂犬病病毒CTN-1V株在人二倍体细胞Walvax-2株的适应传代

目的建立狂犬病病毒固定毒CTN-1V株在人二倍体细胞Walvax-2株上的传代适应株。方法用狂犬病病毒固定毒CTN-1V株经昆明小鼠鼠脑回传后的病毒接种Walvax-2细胞,连续传代,检测各代次病毒的滴度及免疫原性。结果 CTN-1V株能较好地适应Walvax-2细胞,通过连续带毒传代至第7代,病毒滴度可达6.78 lg LD50/mL,并在第10~15代内滴度维持在7.0 lg LD50/mL以上,15~30代滴度稳定在7.0 lg LD50/mL左右。以15代适应毒株CTN-1V-HDC P15制备的疫苗原液,各项指标均符合《中华人民共和国药典》三部(2010版)的要求,疫苗效力在6.0IU/剂以上。结论所获人胚肺二倍体细胞Walvax-2株传代适应狂犬病毒固定毒株CTN-1V-HDC可用于人用狂犬病疫苗的生产开发。     

Evaluation of mouse brain-derived, inactivated Japanese encephalitis vaccine

Japanese encephalitis (JE) is a serious encephalitis caused by JE virus. Approximately 20% of JE patients die and 50% patients recover with neuro-psychiatric sequelae. In Japan, the number of JE patients was over 1000 per year in 1960s; however, the number decreased dramatically and has been less than 10 since 1990. Ministry of Health, Labour and Welfare suspended the strong recommendation for vaccination with the mouse brain-derived JE vaccine, because of cases who developed acute disseminated encephalomyelitis (ADEM) after vaccination with JE vaccine. However, it has not been fully confirmed on scientific bases that ADEM was caused by mouse brain-derived JE vaccine. Tissue culture derived-JE vaccine is under development. It is expected that this new vaccine will come to the market soon and that the recommendation of universal vaccination with JE vaccine will be implemented at the earliest occasion.     

Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties

A system has been developed for generating chimeric yellow fever/Japanese encephalitis (YF/JE) viruses from cDNA templates encoding the structural proteins prM and E of JE virus within the backbone of a molecular clone of the YF17D strain. Chimeric viruses incorporating the proteins of two JE strains, SA14-14-2 (human vaccine strain) and JE Nakayama (JE-N [virulent mouse brain-passaged strain]), were studied in cell culture and laboratory mice. The JE envelope protein (E) retained antigenic and biological properties when expressed with its prM protein together with the YF capsid; however, viable chimeric viruses incorporating the entire JE structural region (C-prM-E) could not be obtained. YF/JE(prM-E) chimeric viruses grew efficiently in cells of vertebrate or mosquito origin compared to the parental viruses. The YF/JE SA14-14-2 virus was unable to kill young adult mice by intracerebral challenge, even at doses of 10(6) PFU. In contrast, the YF/JE-N virus was neurovirulent, but the phenotype resembled parental YF virus rather than JE-N. Ten predicted amino acid differences distinguish the JE E proteins of the two chimeric viruses, therefore implicating one or more residues as virus-specific determinants of mouse neurovirulence in this chimeric system. This study indicates the feasibility of expressing protective antigens of JE virus in the context of a live, attenuated flavivirus vaccine strain (YF17D) and also establishes a genetic system for investigating the molecular basis for neurovirulence determinants encoded within the JE E protein.     

Background of recent JE vaccine issues

In Japan, more than 5,000 patients were reported in 1950, and there have been less than 10 cases annually since 1992. However, Japanese encephalitis virus caused of Japanese encephalitis (JE) are still existed highly and widely in the country, reported by National Institute of Infectious Diseases with serological examination among domestic pig population. JE immunization had been provided to children as category 1 routine immunization in Japan. However, the Ministry of Health, Labor and Welfare (HOHLW) decided not to recommend JE immunization to children as a routine immunization at May 2005. Major reason on this decision was that the Minter of MOHLW certified to pay loss of medical costs for the case of ADEM (acute disseminated encephalomyelopathy) after JE immunization, recognized as adverse events with JE vaccine, although MOHLW stated that the strict scientific evidence was unknown. MOHLW stated also that it is expected Vero cell derived JE vaccine should be replaced with the present mouse brain derived JE vaccine as the next generation, to be able to avoid theoretical possibility of neurological adverse events associated with JE vaccine. Small but increasing number of requests recently to be certified as health injuries on ADEM cases associated with JE immunization is also another reason for MOHLLW's decision. Further, fifth doses of JE vaccine given to children at 14-15 years old as a routine immunization was decided to be discontinued by MOHLW at July 2005, considering present epidemiological situation on JE and JE immunization status in Japan, although four doses has been recommended continuously as routine. The background details on JE vaccine issues decided by MOHLW in 2005 were reviewed on this paper.     

Study on persistent infection of Japanese encephalitis virus Beijing-1 strain in serum-free Sf9 cell cultures

Sf9 cells have obvious advantages for the conventional production technology of vaccine. They are useful tools for high concentration and large-scale cultures. Sf9 cells were grown to maximal concentration, 8 x 10(6) cells/ml in a 500ml spinner flask, with a doubling time at the exponentially growing phase of 24.5 hours, using serum-free media. To explore the ability of Sf9 cells to be infected by the Japanese encephalitis (JE) virus Beijing-1 strain, Sf9 cells were infected with the virus. By 4-5 days post-infection, 10-15% of the Sf9 cells showed cytopathic effect (CPE), from granularity to the formation of syncytia and multinucleated giant cells continuously observed over a period of 35 days. Positive fluorescent reactions were detected in 30-40% of cells infected with the JE virus Beijing-1 strain, and the uninfected Sf9 cells were completely negative. Virus particles, propagated in Sf9 and Vero cells, were concentrated by sedimentation on 40% trehalose cushions by ultracentrifugation, and showed identical patterns of viral morphogenesis. Complete virus particles, 40 to 50 nm in diameter, were observed, and JE virus envelope (E) proteins, at 53 kDa, were found in the western blot analysis to the anti-JE virus E protein monoclonal antibody and reacted as a magenta band in the same position to the glycoprotein staining. To evaluate whether the infectious virus was produced in Sf9 cells inoculated with the JE virus Beijing-1 stain, Sf9 cells were inoculated with the virus, and sample harvested every 5 days. The titers of the JE virus Beijing-1 strain rose from 1.0 x 10(5) to 1.5 x 10(6) pfu/ml. The infected Sf9 cells could be sub-cultured in serum-free medium, with no change in the plaque sizes formed by the JE virus Beijing-1 strain in the plaque assay. It is suggested that the ability of the JE virus Beijing-1 strain to infect Sf9 cells in serum-free media will provide a useful insect cell system, where the JE virus replication, cytopathogenicity and vaccine immunogen can be studied.     

Studies on haemagglutination by the EMC-MM-Columbia SK-group of viruses

Summary When MM and Columbia SK virus were propagated in the chick embryo, the virus disappeared from the allantoic fluid and from the embryonic brain tissue after 6 to 9 chorioallantoic passages. Amniotic passages, however, resulted in a gradual increase of the mouse infectivity titre of the amniotic fluid and of the fluid of the regularly observed subcutaneous edema of the embryos, though after 22 passages the ID50 titre was still 3 logs lower than that of the original mouse brain suspension. The virus was present not only in amniotic fluid, but also in allantoic fluid and throughout the whole embryo. In spite of the pretty high mouse infectivity titres, the extra-embryonic fluids failed to produce haemagglutination of sheep red cells, whereas low haemagglutination titres could be obtained with suspensions of embryonic brain tissue. No evidence was obtained, that a non-specific inhibitor was responsible for the inability to produce haemagglutination. The virus present in egg fluids is only partially adsorbed, which is in contrast with the almost complete adsorption of virus in mouse brain suspension. The adsorption of a relatively small amount of virus might be one of the factors responsible for lack of haemagglutinating ability. It is suggested, that another coinciding factor, which is necessary for the initiation of the haemagglutination might be present in the central nervous system lesion.Third publication: Antonie van Leeuwenhoek17, 137, 1951.     

Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine

We produced and characterized a cell clone (J12#26 cells) that stably expresses Japanese encephalitis virus (JEV) cDNA, J12, which encodes the viral signal peptide, premembrane (prM), and envelope (E) proteins (amino acid positions 105 to 794). Rabbit kidney-derived RK13 cells were transfected with a J12 expression plasmid, selected by resistance to marker antibiotics, and cloned by two cycles of a limiting-dilution method in the presence of antibiotics, a procedure that prevents the successful generation of E-producing cell clones. J12#26 cells secreted virus-like particles containing the authentic E antigen (E-VLP) into the culture medium in a huge enzyme-linked immunosorbent assay-equivalent amount (2.5 micro g per 10(4) cells) to the internationally licensed JE vaccine JE-VAX. E-VLP production was stable after multiple cell passages and persisted over 1 year with 100% expressing cells without detectable cell fusion, apoptosis, or cell death, but was suspended when the cells grew to 100% confluency and contact inhibition occurred. Mice immunized with the purified J12#26 E-antigen without adjuvant developed high titers of neutralizing antibodies for at least 7 months and 100% protection against intraperitoneal challenge with 5 x 10(6) PFU of JEV when examined according to the JE vaccine standardization protocol. These results suggest that the recombinant E-VLP antigen produced by the J12#26 cell clone is an effective, safe, and low-cost second-generation subunit JE vaccine.     

Trypsinized Human Group O Erythrocytes as an Alternative Hemagglutinating Agent for Japanese Encephalitis Virus

Trypsinized human group O erythrocytes were found to be a suitable alternative to gander cells in hemagglutination (HA) and hemagglutination inhibition (HAI) tests for Japanese encephalitis (JE) virus. In the HAI test, no cross-reactions against JE virus were observed with immune sera containing antibody to taxonomically related or unrelated viruses, with mouse brain antigen, or with nonantibody serum inhibitors; specific antibody rise could be detected in an immunized rabbit. Gander and trypsinized human group O cells gave comparable titers in the HAI test, but the latter were preferable since (i) they required less challenging HA antigen, being more sensitive to agglutination by JE virus, and (ii) all human and some animal sera investigated were devoid of natural agglutinins for these cells, thereby eliminating or reducing the need for prior adsorption with packed cells.